Comparative Pharmacology
Head-to-head clinical analysis: EXIDINE versus HIBISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXIDINE versus HIBISTAT.
EXIDINE vs HIBISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EXIDINE (chlorhexidine gluconate oral rinse) is a cationic bisbiguanide antiseptic that disrupts microbial cell membranes by binding to negatively charged bacterial cell walls, causing leakage of intracellular components and cell death.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Active against susceptible gram-positive bacteria.
Apply topically to affected area once or twice daily; oral rinse: 10 mL of 0.05% solution for 30 seconds twice daily (dilute 15 mL of 1% solution in 15 mL water if using concentrate).
1.5 mg/kg intravenously every 6 hours; maximum 120 mg per dose.
None Documented
None Documented
Clinical Note
moderateLofexidine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Lofexidine is combined with Etacrynic acid."
Clinical Note
moderateLofexidine + Furosemide
"The risk or severity of adverse effects can be increased when Lofexidine is combined with Furosemide."
Clinical Note
moderateLofexidine + Bumetanide
"The risk or severity of adverse effects can be increased when Lofexidine is combined with Bumetanide."
Clinical Note
moderateLofexidine + Unoprostone
Terminal half-life is approximately 14 hours, supporting twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Primarily renal (unchanged drug and metabolites); approximately 70% excreted in urine, 30% in feces.
Approximately 90% of absorbed dose excreted renally as unchanged drug; <5% in feces via biliary elimination.
Category C
Category C
Antiseptic
Antiseptic
"Lofexidine may increase the hypotensive activities of Unoprostone."